Isofol Medical AB reported efficacy data for Modufolin® (arfolitixorin) from patients treated during 16weeks form CRC (metastatic colorectal cancer). In this ongoing Phase I/II astudy, ISO-CC-005,Isofol has separately analyzed data from patients in the first line of treatment. The data demonstrates continuous response to treatment between week 8 and week 16. Moreover, none of the treated patients in this group had progressivedisease. To date, 54 patients with mCRC have been treated in the ongoing ISO-CC-005 study. The study evaluates different doses of Modufolin® (arfolitixorin) in combination with 5-FU alone, with or without irinotecan, oxaliplatin ± bevacizumab in first to fifth line of treatment in patients with mCRC. Isofol's planned pivotal study ISO-CC-007, scheduled to begin in mid-2018, will exclusively recruit patients in the first line of treatment. For this purpose, such patients in the ongoing ISO-CC-005 study have now been analyzed separately and the results are the following: As previously informed, after 8 weeks of treatment, 12 patients have been assessed of which 6 patients had partial response (PR) and 6 patients have shown stable disease (SD). Importantly, in the group treated with at least 60 mg/m2 Modufolin® (arfolitixorin), in combination with irinotecan or oxaliplatin all patients (5 out of 5) had partial response (PR). Now, after 16 weeks of treatment, 8 patients have been assessed so far. All 5 patients with partial response at week 8, maintain their response. Furthermore, 3 patients with stable disease at week 8 maintain their response. Hence, no tumor progression occurred between week 8 and 16 for these 1st line treatment patients. The safety profile in this group of patients was consistent with other patients in the study and when compared to historical control.